The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation.
The main questions it aims to answer are:
How effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients?
Participants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.
Patients between 18 and 75 years old
Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation
Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia
Patients agree to sign the informed consent form
Past history or comorbidity of malignant tumor
Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases
Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)
Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician
Patients with dyspepsia symptoms taking Danning Tablets
Cohort
Prospective
Danning Tablet
DrugDanning Tablet is the only exposure in this observational study.
Dyspepsia symptoms responder rate post treatment
A responder status is defined as patients reaching both a decrease of at least 50% regarding the Gastrointestinal Symptom Rating Scale (GSRS) score, and either symptom-free or markedly improved in the Global Patient Assessment (GPA) . GSRS consists of 15 items for assessment of gastrointestinal symptoms. The 15 items include five symptom clusters: Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. Each item is rated on a 7-point Likert scale. The reliability and validity of the GSRS are well-documented. GSRS can be self-administered in approximately 3\~5 minutes. The GPA asks patients the question "Please rate the strength of your upper abdominal complaints in the past 14 days. Please select how much they have changed compared to the condition at the onset of treatment: symptom-free, markedly improved, slightly improved, unchanged, worse".
GPA responder rate
A responder status is defined as patients reaching either symptom-free or markedly improved in the GPA.
GSRS score responder rate
A responder status is defined as patients reaching a decrease of at least 50% regarding the GSRS score.
Abdominal pain rating
Abdominal pain rating is defined as the multiplication of symptom frequency and severity rates. Abdominal pain frequency and severity are recorded in patient diary card. Symptom frequency is rated on a 5-point Likert scale. Symptom severity is rated through Visual Analogue Scale (VAS).
Quality of Life assessment through EQ-5D-5L
TheEuroQol 5 Dimension 5-level (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Click on the lead sponsor to view all of their trials.
Shanghai Hutchison Pharmaceuticals Limited
Lead sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborator
